Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02403284 · ClinicalTrials.gov registry record · Phase 4
The Effect of Liraglutide on Dietary Lipid Induced Insulin Resistance in Humans
A Phase 4 study, sponsored by Phoenix VA Health Care System.
- Completed
- Registry status
- Phase 4
- Development phase
- 97
- Enrollment target
NCT02403284 is a Phase 4 study that has completed, run by Phoenix VA Health Care System. The registered enrollment target is 97 participants.
The verdict
NCT02403284, a Phase 4 study, has completed, sponsored by Phoenix VA Health Care System.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 97 participants
- Enrollment target
Study Summary
In this research study, investigators will test the effects of an approved medication for diabetes,Liraglutide, to reduce insulin resistance that develops from eating a diet high in saturated fats.
Interventions
- DRUG Liraglutide
- DRUG Sugar Pill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 97 participants |
| Start Date | 2013-03 |
| Est. Completion | 2023-11-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02403284
The ClinicalTrials.gov registry entry for NCT02403284 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 97 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Phoenix VA Health Care System, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Liraglutide is the first listed.
NCT02403284 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02403284 about?
NCT02403284 is a clinical study titled "The Effect of Liraglutide on Dietary Lipid Induced Insulin Resistance in Humans". In this research study, investigators will test the effects of an approved medication for diabetes,Liraglutide, to reduce insulin resistance that develops from eating a diet high in saturated fats.
What is the current status of trial NCT02403284?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 97 participants. The study started on 2013-03. Estimated completion is 2023-11-01.
What interventions are being tested in trial NCT02403284?
The interventions under investigation include: Liraglutide (DRUG), Sugar Pill (DRUG).
Who is sponsoring clinical trial NCT02403284?
This trial is sponsored by Phoenix VA Health Care System, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.